Dr. Wojciech Jurczak talks about Continues Therapy versus Time Limited Therapy in High-Risk CLL Patients
Dr. Wojciech Jurczak, Poland
Edit Video Component
Dr. Wojciech Jurczak, MD, PhD, from NIO-PIB im Marii Sklodowskeij-Curie in Krakow, Poland, discusses Continues Therapy versus Time Limited Therapy in High-Risk CLL Patients. During his session, he provided valuable information about targeted therapy being the standard of care for relapsed/refractory CLL patients, discussed on BCL-2 and BTK inhibitors and discussed the evolving landscape of CLL treatment approaches.
Explore more videos
Configure Image Component
Definition and Management of High-Risk CLL Patients
Dr. Ayman Al Hejazi, KSA
Configure Image Component
Panel Discussion
Dr. Ahmad Absi, KSA
Configure Image Component
Latest Updates in Management of CLL
Dr. Davide Rossi, Switzerland
Modal Window Component Section Begins
Modal Window Component Section Ends